Abcentra (United States)

Recent papers from Abcentra (United States)

1. FORTIFY: a phase 2b randomised trial evaluating the effect of orticumab on coronary inflammation (FAI-Score) in post myocardial infarction patients selects for patients with high residual FAI-ScoreEuropean Heart Journal · 2026
2. High prevalence of local coronary arterial inflammation in clinically stable subjects after myocardial infarction: findings from the FORTIFY trial screeneesEuropean Heart Journal · 2026
3. Orticumab: the potential to harness oxidized LDL to reduce coronary inflammation with plaque-targeted therapyCurrent Opinion in Lipidology · 2025
4. Inhibition of oxidized low-density lipoprotein with orticumab inhibits coronary inflammation and reduces residual inflammatory risk in psoriasis: a pilot randomized, double-blind placebo-controlled trialCardiovascular Research · 2024
5. Antibodies against apoB100 peptide 210 inhibit atherosclerosis in apoE-/- miceScientific Reports · 2021